Olimel N9 (Valine, Alanine, Arginine, Histidine, Isoleucine, Leucine, Methionine, Phenylalanine, Proline, Serin)

Olimel N9 is used in clinical nutrition to support patients who require parenteral protein supplementation.

• Parenteral nutrition: supplies essential amino acids to meet protein needs when oral intake is insufficient.
• Critical care: assists in maintaining nitrogen balance in critically ill patients.
• Post‑surgical recovery: supports tissue repair and healing after major surgery.

• Olimel N9 delivers a balanced mixture of essential and non‑essential amino acids directly into the bloodstream, bypassing the gastrointestinal tract. The amino acids serve as substrates for protein synthesis, replenish nitrogen stores, and support metabolic pathways involved in tissue repair, immune function, and energy production during parenteral nutrition.

Adverse reactions to Olimel N9 are generally related to the intravenous route and the amino acid composition.

Common Side Effects

• Mild fever or chills during infusion.
• Transient increase in blood urea nitrogen.
• Local irritation at the infusion site.
• Slight electrolyte imbalance (e.g., potassium).
• Nausea or mild gastrointestinal discomfort.

Serious or Rare Side Effects

• Severe hypersensitivity or anaphylactic reaction.
• Hyperosmolar hyperventilation syndrome.
• Metabolic acidosis.
• Significant electrolyte disturbances (e.g., hyperkalemia).
• Renal function deterioration.

When using Olimel N9, clinicians should consider several safety measures.

• Renal function: assess baseline kidney function before initiation.
• Electrolyte monitoring: regularly check serum electrolytes during therapy.
• Fluid balance: adjust infusion volume to avoid fluid overload.
• Metabolic status: monitor acid‑base balance in patients at risk.
• Compatibility: verify compatibility with other intravenous solutions before mixing.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Olimel N9 may interact with other intravenous therapies and metabolic modulators.

Major Interactions (Avoid)

• High‑dose potassium chloride: may cause dangerous hyperkalemia when combined.
• Acidifying agents: can exacerbate metabolic acidosis.

Moderate Interactions (Monitor Closely)

• Loop diuretics: may increase electrolyte loss, requiring closer monitoring.
• Insulin therapy: amino acids stimulate insulin release, affecting glucose control.
• Other parenteral nutrition formulations: risk of excess amino acid dosing.
• Citrate anticoagulants: may alter calcium balance during infusion.